FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Has finished Phase 1 of its exosome therapy ILB-202 and is preparing GMP clinical supply and wider indications.

  • Was selected for a government program supporting GMP production of ILB-202 clinical supply. Source
  • Published ILB-202 Phase 1 results in an international journal. Source

Roles often seen at this stageResearch & development · Clinical & PV · Manufacturing & MSAT

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

ILIAS Biologics

Develops exosome therapeutics for inflammatory diseases using its own EXPLOR exosome engineering platform.

ILB-202

Phase 1

An anti-inflammatory exosome candidate that inhibits NF-κB signaling; a randomized, double-blind Phase 1 in healthy volunteers showed safety and tolerability at all doses.

Completion reported

Was selected for a Ministry of Health and Welfare program that supports GMP production of ILB-202 clinical drug substance.

Completion reported

Published ILB-202 Phase 1 results in the Journal of Extracellular Vesicles.

Completion reported

Gave an investor presentation at Biotech Showcase 2026 in San Francisco.

Official role guide

ILIAS Biologics careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 일리아스바이오로직스, 엑소좀 기반 신약 ILB-202 1상 결과 국제 학술지에 게재 ↗바이오타임즈 · Published 2025-09-29 · Sources checked 2026-11-18 · Original unavailable
  2. 일리아스, 「첨단의료산업선도기반실증지원사업」 선정∙∙∙적응증 확장 통한 글로벌 경쟁력↑ ↗바이오타임즈 · Published 2025-09-03 · Sources checked 2026-11-18 · Original unavailable
  3. 일리아스바이오로직스, 'Biotech Showcase 2026'서 기업발표(IR) ↗머니투데이 · Published 2026-01-20 · Sources checked 2026-11-18 · Original unavailable